poor ovarian response. R00_R99
Conditions
Interventions
Intervention 1: In control group ovarian stimulation will be done by using 225 IU Follicle_Stimulating Hormone(Gonal-F,MERC, italy) and 150 IU human Menopausal Gonadotropine(Pergonal, Serono, Swithsze
Treatment - Drugs
In control group ovarian stimulation will be done by using 225 IU Follicle_Stimulating Hormone(Gonal-F,MERC, italy) and 150 IU human Menopausal Gonadotropine(Pergonal, Serono, Swithszerland) started a
In intervention group ovarian stimulation will be done by using 225 IU Follicle_Stimulating Hormone(Gonal-F, MERC, italy) and 150 IU human Menopausal Gonadotropine(Pergonal, Serono, Swithszerland) sta
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
30 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Infertile female who are reffered to InVitro Fertillization Department of Jaame_Zanan Hospital candidates for InVitro fertillization or IntraCytoplasmic Sperm Injection; females aged over 30 years old; females diagnosed as poor ovarian responders. Females should have at least one of listing criterias to be classified as poor responders: previous cancled cycle due to poor ovarian response in an InVitro fertillization or IntraCytoplasmic Sperm Injection cycle (defined as having 3 or less oovocytes retrieved or serum estradiol less than 500 pg/ml), serum Follicle_Stimulating Hormone over 10 U/ml and age above 40 years old. Exclusion criterias are: Infertile females having all inclusion criterias but do not wish to be included in the project; females who show letrozole hypersensivity reactions or serious intolerable side effects of letrozole; females over 50 years old; having endocrine disorders such as thyroid dysfunction, hyperprolactinemia or diabetes;previous ovarian surgery; having a follicle larger than 10 mm at third day of menstural cycle; history of OHSS in previous ART cycle; uncorrected Mullerian anomaly; active renal or hepatic diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oocytes retrieved number. Timepoint: at the end of ovarian stimulation cycle. Method of measurement: oovocyte retrieved containing both metaphase1 and 2 counted under microscopic examination by genetician.;Embrios transferred. Timepoint: at the end of cycle after 3-day growth of invitro. Method of measurement: counting embrios under microscopic examination by genetician.;Endometrial thickness. Timepoint: on the day of hCG administration. Method of measurement: measured by transvaginal sonograghy by gynecologist.;Total gonadotropin dose. Timepoint: after oovocyte puncture. Method of measurement: number of 75 IU gonadotropin ampules used till oovocyte puncture. | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate per cycle. Timepoint: at the end of project. Method of measurement: SPSS softeware.;Clinical pregnancy rate per emberio transfer. Timepoint: at the end of project. Method of measurement: SPSS softeware.;Implantation rate per cycle. Timepoint: at the end of project. Method of measurement: SPSS softeware.;Implantation rate per emberio transfer. Timepoint: at the end of project. Method of measurement: SPSS softeware.;Cancelation rate per cycle. Timepoint: at the end of project. Method of measurement: SPSS softeware. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyede Mojgan Ghalandarpoorattar
Jaame_Zanan Hospital
Outcome results
None listed